ZEOX · Zeo ScientifiX, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“As of April 30, 2026, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements. In addition, the Company's independent registered public accounting firm, in its report on the Company's October 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jun 15, 2026
One customer — 14.2% of revenue (the six months ended April 30, 2026)
“During the six months ended April 30, 2026, the Company sold products and services totaling approximately $571,000 (14.2%) to a large medical practice group and distributor”
One customer — 12.7% of revenue (the six months ended April 30, 2026)
“and approximately $511,000 (12.7%) to another large medical practice group and distributor.”
One customer — 15.2% of revenue (the six months ended April 30, 2025)
“$341,000 (15.2%)”
One customer — 12.1% of revenue (the six months ended April 30, 2025)
“During the six months ended April 30, 2025, the Company sold products and services totaling approximately $270,000 (12.1%) to a large distributor”
One customer — 10.2% of revenue (the six months ended April 30, 2025)
“and $228,000 (10.2%) to two individual medical practices.”
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $6.99M | $5.2M | $4.62M | $4.56M | $6.49M | $5.6M | $3.06M | $1.7M | $964.53K | $569.85K | $184.88K | $147.63K | $49.2K | $82.97K | $87.15K | $18.08K | |
| — | — | — | — | — | -$37.93K | -$177.74K | — | — | — | — | — | — | — | — | — | |
| $1.29M | $931K | $844K | $508K | $753.53K | $547.88K | $398.61K | $300.84K | $209.3K | $160.63K | $94.4K | $49.41K | $20.06K | $44.44K | $61.12K | $10.99K | |
| $5.7M | $4.27M | $3.78M | $4.05M | $5.74M | $5.05M | $2.66M | $1.4M | $755.23K | $409.22K | $90.48K | $98.22K | $29.14K | $38.53K | $26.03K | $7086 | |
| — | 82.09% | 81.73% | 88.85% | 88.39% | 90.21% | 86.96% | 82.33% | 78.3% | 71.81% | 48.94% | 66.53% | 59.23% | 46.44% | 29.87% | 39.19% | |
| — | $100K | $164K | $922.7K | $791.3K | $1.12M | $233.53K | $54.86K | — | — | — | — | — | — | — | — | |
| $9.83M | $9.65M | $9.1M | $10.82M | $14.58M | $17.79M | $15.1M | $3.18M | $4.25M | $9.05M | $1.13M | $842.53K | $94.96K | $43.65K | $14.48K | $5572 | |
| $77K | $73K | $74K | $486K | $332.51K | $52.7K | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $9.05M | $1.13M | — | $94.96K | $70.7K | $38.37K | $18.81K | |
| -$4.13M | -$5.39M | -$5.32M | -$6.77M | -$8.84M | -$12.74M | -$12.44M | -$1.78M | -$3.49M | -$8.64M | -$1.04M | -$744.31K | — | — | — | — | |
| — | -103.6% | -115.13% | -148.49% | -136.23% | -227.68% | -407.03% | -104.36% | -361.85% | -1516.47% | -564.32% | -504.18% | — | — | — | — | |
| -$4.05M | -$5.31M | -$5.25M | -$6.28M | -$8.51M | -$12.69M | — | — | — | — | — | — | — | — | — | — | |
| $76K | $98K | $92K | $431K | $398.26K | $37.93K | $177.74K | $46.6K | $228.33K | $576.02K | $12.73K | — | — | — | — | — | |
| -$146K | -$136K | $613K | -$10K | $249.5K | $25.48K | $32.72K | $84.79K | $21.43K | $9050 | $0 | — | — | — | — | — | |
| -$9.49M | — | — | — | -$8.9M | -$12.76M | -$12.58M | -$1.74M | -$3.43M | -$9.11M | — | — | — | — | — | — | |
| — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | |
| -$3.88M | -$5.52M | -$4.71M | -$6.99M | -$8.9M | -$12.76M | -$12.58M | -$1.74M | -$3.46M | -$8.97M | -$1.25M | -$738.35K | -$65.82K | -$32.18K | -$13.34K | -$11.73K | |
| — | -106.19% | -101.84% | -153.29% | -137.06% | -227.9% | -411.78% | -102.06% | -358.95% | -1574.49% | -677.84% | -500.14% | -133.78% | -38.78% | -15.3% | -64.85% | |
| — | — | — | — | — | — | $0 | -$978 | $30.75K | -$140.39K | $0 | — | — | — | — | — | |
| USD/shares | -$0.58 | -$0.86 | -$0.74 | -$0.99 | -$1.56 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$0.58 | -$0.86 | -$0.74 | -$0.99 | -$1.56 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 6.41M | 6.34M | 7.03M | 5.69M | 5.3M | 3.35M | 2.33M | 1.36M | 542.98K | 501.89K | 670.24K | 750.6K | 39.85K | 37.5K | 7807.205 |
| shares | — | 6.41M | 6.34M | 7.03M | 5.69M | 5.3M | 3.35M | 2.33M | 1.36M | 542.98K | 501.89K | 670.24K | 750.6K | 39.85K | 37.5K | 7807.205 |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Convertible debt, including current maturities | 2026-04-30 | USD 250,000 | 10-Q filed 2026-06-15 |
| Current portion of convertible notes payable | 2026-04-30 | USD 247,000 | 10-Q filed 2026-06-15 |
| Current portion of long-term debt | 2026-04-30 | USD 247,000 | 10-Q filed 2026-06-15 |
| Finance lease liabilities | 2026-04-30 | USD 96,000 | 10-Q filed 2026-06-15 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 215 similar-size Biotechnology companies (of 559 listed).